New York, USA – December 7, 2022 – Metabolomics, a division of Creative Proteomics, is dedicated to providing cutting-edge LC-MS-based metabolomics services for biomedical research institutions as well as biotechnological and pharmaceutical companies. The company launches the drug-resistant metabolomics research service for oncology research and infectious disease studies regarding drug resistance.
Drug therapy is one of the major modalities for cancer treatment. However, drug resistance may reveal whether it is chemotherapy drugs, targeted drugs, or immunotherapy drugs. Once drug resistance (especially multidrug resistance) is developed, cancer proliferation tends to progress faster or recurs, eventually leading to treatment failure.
Tumor drug resistance has long been a key direction of cancer research. Meanwhile, complex factors and multiple mechanisms are known to induce drug resistance occurrence or reoccurrence, covering tumor heterogeneity, DNA damage repair, apoptosis inhibition, epithelial-mesenchymal transition, increased drug excretion or reduced absorption, decreased drug activity, altered drug metabolism, altered drug target, and tumor microenvironment. These factors and mechanisms may present individually or in combination within patients. Furthermore, epigenetic alterations, transporter protein abnormalities, non-coding RNA abnormalities, and exosomal modifications may also directly or indirectly contribute to the occurrence of drug resistance mechanisms.
Creative Proteomics provides the following metabolomics solutions for drug-resistant research:
1. Bacterial/fungal/viral/parasitic resistance studies: the metabolic state of bacteria is associated with a range of genetic and phenotypic resistance mechanisms. Thus, metabolomics is used to determine the relationship between antimicrobial resistance (AMR) mechanisms and microbial metabolism.
2. Tumor drug resistance studies: tumor cells develop drug resistance with corresponding changes in metabolic patterns, and the same drug acting on sensitive and resistant cells can result in different metabolic changes. Thus, metabolomics is used to detect metabolic changes and responses so as to determine drug resistance within tumor cells and monitor related at early stages, including research on the multidrug resistance mechanisms and invasive metastasis of tumors.
3. Frequently analyzed pathways include: the protein synthesis pathway, the cysteine synthesis pathway, the glutamine metabolism pathway, the phenylalanine metabolism pathway, the ammonia cycle, and other metabolic pathway analyses.
“We employ state-of-the-art analytical platforms for drug-resistant metabolomics studies, including GC-MS, LC-MS, and UPLC-MS. With strong expertise in handling a variety of sample types, we are able to ensure the best recovery and unbiased metabolome measurement,” said the senior scientist of Creative Proteomics.
The primary instruments utilized in metabolomics analysis include AN Sciex Qtrap 6500 Plus, AB 5600 Triple TOF, Agilent 7890-5977, and Thermo TSQTM 9000. Creative Proteomics has deep industry and business process expertise, global resources, and a good reputation for providing contract research services specialized in metabolomics.
About Creative Proteomics
As an experienced supplier of proteomics, metabolomics, and bioinformatics services, Creative Proteomics has been well-equipped with advanced technologies in order to meet the increasing needs of researchers and scientists in their proteomics- and metabolomics-related research.